Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. [electronic resource]
Producer: 20091103Description: 1430-8 p. digitalISSN:- 1873-7560
- Aged
- Antineoplastic Agents -- administration & dosage
- Benzenesulfonates -- administration & dosage
- Carcinoma, Renal Cell -- drug therapy
- Chemotherapy, Adjuvant
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Humans
- Indoles -- administration & dosage
- Kidney Neoplasms -- drug therapy
- Magnetic Resonance Imaging -- methods
- Male
- Middle Aged
- Neoplasm Metastasis
- Neoplasm Recurrence, Local -- mortality
- Neoplasm Staging
- Nephrectomy -- methods
- Niacinamide -- analogs & derivatives
- Phenylurea Compounds
- Protein Kinase Inhibitors -- administration & dosage
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Pyridines -- administration & dosage
- Pyrroles -- administration & dosage
- Retrospective Studies
- Risk Assessment
- Sorafenib
- Sunitinib
- Survival Analysis
- Tomography, X-Ray Computed -- methods
- Treatment Outcome
- Withholding Treatment
No physical items for this record
Publication Type: Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.